Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

A new era of early cancer detection with blood test may change cancer screening paradigms

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

Lasofoxifene shows promise for women with ESR1-mutated mBC

New data presented at ESMO for multi-cancer early detection

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence

Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours